Clinical Trials Logo

Filter by:
NCT ID: NCT06195501 Recruiting - Clinical trials for Ischemic Stroke, Acute

Dysphagia After Transesophageal Echocardiography in Acute Stroke - Follow Up Trial

TEDRAS2
Start date: May 1, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of the prospective observational TEDRAS - Follow-up Trial is to investigate the limitations of the initial TEDRAS - Trial in patients with acute Dysphagia is a common consequence from ischemic stroke and it correlates with an increased risk of pulmonary complications such as aspiration pneumonia and an increased mortality risk. TEDRAS-Trial (Transesophageal Echocardiography: Dysphagia Risk in the Acute Phase After Stroke; ClinTrial.gov identifier NCT04302883) was the first randomized and controlled trial to address the question of the extent to which TEE increases dysphagia risk in acute stroke patients. The results of the study confirmed the hypothesis that dysphagia severity worsens after TEE in the intervention group. The aim of the prospective observational TEDRAS - Follow-up Trial is to investigate the limitations of the initial TEDRAS - Trial in patients with acute ischemic stroke.

NCT ID: NCT06194032 Completed - Clinical trials for Healthy Participants

A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants

Start date: February 29, 2024
Phase: Phase 1
Study type: Interventional

This study will assess the effect of single oral doses of baxdrostat on the ECG interval measured from the onset of the QRS complex to the end of the T wave (QT) interval corrected for HR using Fridericia's formula (QTcF) compared to placebo using a concentration-QTcF analysis, and with moxifloxacin as positive control, in healthy participants.

NCT ID: NCT06193811 Completed - Healthy Clinical Trials

A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood

Start date: January 16, 2024
Phase: Phase 1
Study type: Interventional

The main objective of this trial is to investigate: - the relative bioavailability of Avenciguat (BI 685509) TF2 (Reference, R) vs. Avenciguat (BI 685509) iCF (Test 1, T1) tablets under fasted conditions - the relative bioavailability of Avenciguat (BI 685509) iCF tablets under fasted (T1) and fed (Test 2, T2) conditions - the relative bioavailability of Avenciguat (BI 685509) iCF tablets given alone (T1) and together with esomeprazole (Test 3, T3) under fasted conditions

NCT ID: NCT06193668 Recruiting - Clinical trials for Lipid-induced Insulin Resistance

Overfeeding Induced Fat-tissue Stimulation

OVID_FASTI
Start date: January 31, 2024
Phase: N/A
Study type: Interventional

Type 2 diabetes is the most common metabolic disease worldwide, characterized by hyperglycemia, decreased whole body insulin sensitivity, and white adipose tissue (WAT) dysfunction. A key factor in its development is chronic overnutrition, usually with a high-fat diet (HFD), leading to disturbances of glucose and lipid metabolism. However, the mechanism of short-term HFD-induced tissue-specific insulin resistance remains poorly understood. This project aims to further unravel the underlying mechanisms of short-term HFD overnutrition-mediated WAT insulin resistance. The model described here corresponds to a randomized, single- blinded parallel-grouped trial, consisting of two interventions: a macronutrient-balanced diet and or a hypercaloric diet over three weeks in order to investigate differences in interorgan fatty acid and glucose metabolism between the studied groups. Based on recent studies, the hypothesis is that 21-day hypercaloric HFD induces WAT insulin resistance via a diacylglycerol, novel protein kinase C-insulin receptor signaling model in both fasting and insulin-stimulated states.

NCT ID: NCT06193200 Recruiting - Clinical trials for Ataxia Telangiectasia

To Evaluate the Effects of EryDex in Patients With A-T

NEAT
Start date: June 2024
Phase: Phase 3
Study type: Interventional

This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate [DSP] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangectasia (A-T).

NCT ID: NCT06192914 Recruiting - Allergy Clinical Trials

EPAP, Interviewstudy

Start date: March 1, 2022
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn about repetitive anaphylactic reactions in food allergic patients and to compare the frequency of repetitive reactions between different elicitors in food allergic patients. The main question it aims to answer are: • Is there an elicitor specific difference in the occurrence of anaphylactic reactions once the elicitor has been identified and the patient received counselling about its avoidance? Participants will answer questionnaires via a link they will receive via e-mail at baseline and 3, 6, 12 and 24 months after inclusion in the study.

NCT ID: NCT06192420 Completed - Ankle Sprain Clinical Trials

TRAUMED - a Clinical Trial in Acute Ankle Sprain

TRAUMED
Start date: February 26, 2018
Phase: Phase 3
Study type: Interventional

TRAUMED - a randomized clinical trial evaluating the efficacy and safety of Traumed® gel in patients with acute ankle sprain.

NCT ID: NCT06192355 Recruiting - Clinical trials for Upper Gastrointestinal Bleeding

Single-use Versus Reusable Gastroscopes in Patients With Upper Gastrointestinal Bleeding.

OneScopeII
Start date: March 27, 2023
Phase: N/A
Study type: Interventional

Controlled-randomized trial evaluating single-use versus reusable gastroscopes in patients with upper gastrointestinal bleeding.

NCT ID: NCT06192108 Recruiting - Type 2 Diabetes Clinical Trials

A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

ACHIEVE-2
Start date: January 10, 2024
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.

NCT ID: NCT06191952 Recruiting - Alzheimer Dementia Clinical Trials

Davos Alzheimer's Collaborative Healthcare System Preparedness to Increase Cognitive Assessment Rates for Older Adults

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

In this study the investigators explore a pragmatic strategy to increase cognitive screening rates in the community. The investigators will compare the monetary value of different combinations of SCD questionnaires, digital cognitive tests, and blood Alzheimer's Disease (AD) biomarkers to identify the best approach for primary care settings.